Ribozymes against TGFβ1 reverse character of activated hepatic stellate cells in vitro and inhibit liver fibrosis in rats

Journal of Gene Medicine

Volumn 7, Issue 7, 2005, Pages 965-976

  Song, Yu Hu ^a,b   Chen, Xiang Long ^b   Kong, Xin Juan ^a   Liu, Nan Zhi ^a   Li, Wei ^b   Wu, Xiao Li ^a   Lin, Ju Sheng ^a   Jin, You Xin ^b  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b INSTITUTE OF BIOCHEMISTRY AND CELL BIOLOGY   (China)

Author keywords

Gene therapy; Hepatic stellate cell; Liver fibrosis; RNA, catalytic; U1 snRNA

Indexed keywords

ADENOVIRUS VECTOR; ALPHA SMOOTH MUSCLE ACTIN; BROXURIDINE; CARBON TETRACHLORIDE; COLLAGEN; COLLAGEN TYPE 1; DESMIN; MESSENGER RNA; RIBOZYME; SMALL NUCLEAR RNA; TRANSFORMING GROWTH FACTOR BETA1; GAMMA INTERFERON; TRANSFORMING GROWTH FACTOR BETA; U1 SMALL NUCLEAR RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ACTIVATION; CELL FREE SYSTEM; CELL PROLIFERATION; CELLULAR DISTRIBUTION; COLLAGEN SYNTHESIS; CONTROLLED STUDY; DISEASE MODEL; DOWN REGULATION; DRUG ACTIVITY; DRUG DESIGN; DRUG TARGETING; ENZYME DEGRADATION; GENE CASSETTE; GENE EXPRESSION; GENETIC TRANSFECTION; HISTOPATHOLOGY; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; LIVER FIBROSIS; MOLECULAR CLONING; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; STELLATE CELL; TREATMENT OUTCOME; VIRAL GENE DELIVERY SYSTEM; ANIMAL; BIOLOGICAL MODEL; CELL CULTURE; CHEMICALLY INDUCED DISORDER; CYTOLOGY; DRUG EFFECT; GENE VECTOR; GENETICS; LIVER; LIVER CIRRHOSIS; METABOLISM; MOLECULAR GENETICS;

ANIMALS; BASE SEQUENCE; CELL PROLIFERATION; CELL-FREE SYSTEM; CELLS, CULTURED; COLLAGEN TYPE I; GENETIC VECTORS; INTERFERON TYPE II; LIVER; LIVER CIRRHOSIS; MODELS, BIOLOGICAL; MOLECULAR SEQUENCE DATA; RATS; RNA, CATALYTIC; RNA, SMALL NUCLEAR; TRANSFECTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 22544448995     PISSN: 1099498X     EISSN: None     Source Type: Journal    
DOI: 10.1002/jgm.744     Document Type: Article

References (46)

1. Friedman SL. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem 2000; 275: 2247-2250.
2. Friedman SL. The cellular basis of hepatic fibrosis: mechanism and treatment strategies. New Engl J Med 1993; 328: 1828-1835.
3. Friedman SL. Liver fibrosis-from bench to bedside. J Hepatol 2003; 38: S39-S53.
4. Mallat A, Preaux A, Blazejewski S, et al. Interferon alpha and gamma inhibit proliferation and collagen synthesis of human Ito cells in culture. Hepatology 1995; 21: 1003-1010.
5. Rockey DC, Maher JJ, Jarnagin WR, et al. Inhibition of rat hepatic lipocyte activation in culture by interferon-gamma. Hepatology 1992; 16: 776-784.
6. Baroni GS, Ambrosio LD, Curto P, et al. Interferon gamma decreases hepatic stellate cell activation and extracellular matrix deposition in rat liver fibrosis. Hepatology 1996; 23: 1189-1199.
7. Bataller R, Brenner DA. Hepatic stellate cells as a target for the treatment of liver fibrosis. Semin Liver Dis 2001; 21: 437-451.
8. Shimizu I, Mizobuchi Y, Yasuda M, et al. Inhibitory effect of oestradiol on activation of rat hepatic stellate cells in vivo and in vitro. Gut 1999; 44: 127-136.
9. Williams EJ, Benyon RC, Trim N, et al. Relaxin inhibits effective collagen deposition by culture hepatic stellate cells and decreases rat liver fibrosis in vivo. Gut 2001; 49: 577-583.
10. Okuno M, Akita K, Moriwaki H, et al. Prevention of rat hepatic fibrosis by the protease inhibitor, camostat mesilate, via reduced generation of active TGF-β. Gastroenterology 2001; 120: 1784-1800.
11. Wang YQ, Ikeda K, Ikebe T, et al. Inhibition of hepatic stellate cell proliferation and activation by the semisynthetic analogue of fumagillin TNP-470 in rats. Hepatology 2002; 32: 980-989.
12. Sario AD, Bendia E, Baroni GS, et al. Effect of pirfenidone on rat hepatic stellate cell proliferation and collagen production. J Hepatol 2002; 37: 584-591.
13. Galli A, Crabb DW, Ceni E, et al. Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro. Gastroenterology 2002; 122: 1924-1940.
14. George J, Roulot D, Koteliansky VE, et al. In vivo inhibition of rat stellate cell activation by soluble transforming growth factor beta type II receptor: a potential new therapy for hepatic fibrosis. Proc Natl Acad Sci U S A 1999; 96: 12 719-12 724.
15. Yata Y, Gotwals P, Koteliansky V, et al. Dose-dependent inhibition of hepatic fibrosis in mice by a TGF-β soluble receptor: implications for antifibrotic therapy. Hepatology 2002; 35: 1022-1030.
16. Shimizu I, Ma YR, Mizobuchi Y, et al. Effects of sho-saiko-to, a Japanese herbal medicine, on hepatic fibrosis in rats. Hepatology 1999; 29: 149-160.
17. Ueki T, Kaneda Y, Tsutsui H, et al. Hepatocyte growth factor gene therapy of liver cirrhosis in rats. Nat Med 1999; 5: 226-230.
18. Qi Z, Atsuchi N, Ooshima A, et al. Blockade of type beta transforming growth factor signaling preventing liver fibrosis and dysfunction in the rat. Proc Natl Acad Sci U S A 1999; 96: 2345-2349.
19. Nakamura T, Sakata R, Ueno T, et al. Inhibition of transforming growth factor beta prevents progression of liver fibrosis and enhances hepatocyte regeneration in dimethylnitrosamine - treated rats. Hepatology 2000; 32: 247-255.
20. Rudolph KL, Chang S, Millard M, et al. Inhibition of experimental liver cirrhosis in mice by telomerase gene delivery. Science 2000; 287: 1253-1258.
21. Takayama H, LaRochelle WJ, Sharp R, et al. Diverse tumorigenesis associated with aberrant development in mice over-expressing hepatocyte growth factor/scatter factor. Proc Natl Acad Sci USA 1997; 94: 701-706.
22. Kulkarni AB, Huh C, Becker D, et al. Transforming growth factor β1 null mutation in mice causes excessive inflammatory response and early death. Proc Natl Acad Sci U S A 1993; 90: 770-774.
23. Song E, Chen J, Wang K, et al. Intrasplenic transplantation of syngeneic hepatocytes modified by IFN-gamma gene ameliorates hepatic fibrosis in rats. Transpl Int 2002; 15: 472-478.
24. Arias M, Lahme B, Van de Leur E, et al. Adenoviral delivery of an antisense RNA complementary to the 3′ coding sequence of transforming growth factor-beta1 inhibits fibrogenic activities of hepatic stellate cells. Cell Growth Differ 2002; 13: 265-273.
25. Muotri AR, da Veiga Pereira L, dos Reis Vasques L, et al. Ribozymes and the anti-gene therapy: how a catalytic RNA can be used to inhibit gene function. Gene 1999; 237: 303-310.
26. Samarsky DA, Ferbeyre G, Bertrand E, et al. A small nucleolar: ribozyme hybrid cleaves a nucleolar RNA target in vivo with near-perfect efficiency. Proc Natl Acad Sci U S A 1999; 96: 6609-6614.
27. Rossi JJ. Ribozymes in the nucleolus. Science 1999; 285: 1685.
28. Green MR. Biochemical mechanisms of constitutive and regulated pre-mRNA splicing. Annu Rev Cell Biol 1991; 7: 559-599.
29. Michienzi A, Prislei S, Bozzoni I. U1 small nuclear RNA chimeric ribozymes with substrate specificity for the Rev pre-mRNA of human immunodeficiency virus. Proc Natl Acad Sci U S A 1996; 93: 7219-7224.
30. Montgomery RA, Dietz HC. Inhibition of fibrillin 1 expression using U1 snRNA as a vehicle for the presentation of antisense targeting sequence. Hum Mol Genet 1997; 6: 519-525.
31. Michienzi A, Conti L, Varano B, et al. Inhibition of human immunodeficiency virus type 1 replication by nuclear chimeric anti-HIV ribozymes in a human T lymphoblastoid cell line. Hum Gene Ther 1998; 9: 621-628.
32. Liu R, Li W, Karin NJ, et al. Ribozyme ablation demonstrates that the cardiac subtype of the voltage-sensitive calcium channel is the molecular transducer of 1,25-dihydroxyvitamin D(3)-stimulated calcium influx in osteoblastic cells. J Biol Chem 2000; 275: 8711-8718.
33. Jiang WG, Grimshaw D, Lane J, et al. A hammerhead ribozyme suppresses expression of hepatocyte growth factor/scatter factor receptor c-MET and reduces migration and invasiveness of breast cancer cells. Clin Cancer Res 2001; 7: 2555-2562.
34. Bartlett JS, Sethna M, Ramamurthy L, et al. Efficient expression of protein coding genes from the murine U1 small nuclear RNA promoters. Proc Natl Acad Sci U S A 1996; 93: 8852-8857.
35. Lin JS, Song YX, Kong XJ, et al. Preparation and identification of anti-transforming growth factor β1 U1 small nuclear RNA chimeric ribozyme in vitro. World J Gastroenterol 2003; 9: 572-577.
36. Vogel S, Piantedosi R, Frank J, et al. An immortalized rat liver stellate cell line (HSC-T6): a new cell model for the study of retinoid metabolism in vitro. J Lipid Res 2000; 41: 882-893.
37. Kim Y, Ratziu V, Choi SG, et al. Transcriptional activation of transforming growth factor beta1 and its receptors by the Kruppel-like factor Zf9/core promoter-binding protein and Sp1. Potential mechanisms for autocrine fibrogenesis in response to injury. J Biol Chem 1998; 273: 33 750-33 758.
38. Wells RG. FibrogenesisV. TGF-β signaling pathways. Am J Physiol Gastrointest Liver Physiol 2000; 279: G845-850.
39. Bissel DM, Roulot D, George J. Transforming growth factor β and liver. Hepatology 2001; 34: 859-867.
40. Olaso E, Ikeda K, Eng FJ, et al. DDR2 receptor promotes MMP-2-mediated proliferation and invasion by hepatic stellate cells. J Clin Invest 2001; 108: 1369-1378.
41. Olaso E, Labrador JP, Wang L, et al. Discoidin domain receptor 2 regulates fibroblast proliferation and migration through the extracellular matrix in association with transcriptional activation of matrix metalloproteinase-2. J Biol Chem 2002; 277: 3606-3613.
42. Ikeda K, Wang LH, Torres R, et al. Discoidin domain receptor 2 interacts with Src and Shc following its activation by type I collagen. J Biol Chem 2002; 277: 19 206-19 212.
43. Schnabl B, Kweon YO, Frederick JP, et al. The role of Smad3 in mediating mouse hepatic stellate cell activation. Hepatology 2001; 34: 89-100.
44. Maher JJ. Interactions between hepatic stellate cells and the immune system. Semin Liver Dis 2001; 21: 417-426.
45. Hellerbrand C, Stefanovic B, Giordano F, Burchardt ER, Brenner DA. The role of TGFβ1 in initiating hepatic stellate cell activation in vivo. J Hepatol 1999; 30: 77-87.
46. Beljaars L, Molema G, Schuppan D, et al. Successful targeting to rat hepatic stellate cells using albumin modified with cyclic peptides that recognize the collagen type VI receptor. J Biol Chem 2000; 275: 12 743-12 751.